1. Pink Sheet

FTC's Merger Concerns Remain Despite Amgen’s ‘Bare Commitment’ Not To Bundle Horizon Drugs

 
• By Brenda Sandburg

The commission seeks a preliminary injunction by 31 October to block the closing of the proposed Amgen-Horizon merger. Harvard Professor Aaron Kesselheim, FTC’s expert, says Amgen could circumvent a commitment not to bundle its and Horizon's products. The Pfizer-Seagen merger agreement also gets a second request for information.

FTC building
The FTC wants a preliminary injunction to block Amgen's acquisition of Horizon. • Source: Shutterstock

The US Federal Trade Commission doubled down on its efforts to halt the close of Amgen, Inc.’s proposed acquisition of Horizon Therapeutics plc until a final decision is made on its administrative complaint opposing the deal, asking a district court to issue a preliminary injunction by 31 October.

In a redacted 14 July memorandum supporting a preliminary injunction, the FTC and six states reiterated that post-merger, Amgen...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

HHS Wants Employees (And Public?) To Report Diversity, Equity And Inclusion Discrimination

 
• By Sue Sutter

A survey asks FDA staff to disclose whether DEI policies caused discrimination or resulted in disciplinary action against career employees over the past five years, but uses a web form that the general public also can access.

EU Health Chief Declares There Is No Better Alternative Than TEVs to Spark Antibiotic Innovation

 
• By Francesca Bruce

Clarity on what transferable exclusivity vouchers may look like for new antimicrobial drugs could be nearing. Denmark’s new presidency of the Council of the EU has prioritized concluding its negotiations with European Parliament over the legislative overhaul of the EU’s pharmaceutical legislation.

EU Fines Alchem Over Buscopan API Cartel

 
• By Dave Wallace

After pursuing Alchem International for breaches of EU antitrust rules – relating to a cartel over the SNBB pharmaceutical ingredient used in Buscopan and its generics – the European Commission has now hit the firm with a €489,000 fine.